372 related articles for article (PubMed ID: 31117914)
1. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
[TBL] [Abstract][Full Text] [Related]
2. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
4. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in China: development and challenges.
Zhao Y; Wang T; Li G; Sun S
Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
[TBL] [Abstract][Full Text] [Related]
7. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.
Bennett CL; Schooley B; Taylor MA; Witherspoon BJ; Godwin A; Vemula J; Ausdenmoore HC; Sartor O; Yang YT; Armitage JO; Hrushesky WJ; Restaino J; Thomsen HS; Yarnold PR; Young T; Knopf KB; Chen B
PLoS One; 2019; 14(7):e0219521. PubMed ID: 31365527
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance in oncology.
Baldo P; Fornasier G; Ciolfi L; Sartor I; Francescon S
Int J Clin Pharm; 2018 Aug; 40(4):832-841. PubMed ID: 30069667
[TBL] [Abstract][Full Text] [Related]
9. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
Poirot E; Soble A; Ntshalintshali N; Mwandemele A; Mkhonta N; Malambe C; Vilakati S; Pan S; Darteh S; Maphalala G; Brown J; Hwang J; Pace C; Stergachis A; Vittinghoff E; Kunene S; Gosling R
Malar J; 2016 Jul; 15(1):384. PubMed ID: 27450652
[TBL] [Abstract][Full Text] [Related]
10. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
[TBL] [Abstract][Full Text] [Related]
11. Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital.
Mendes D; Abrantes J; Rigueiro G; Pais AF; Penedones A; Alves C; Batel-Marques F
J Oncol Pharm Pract; 2021 Sep; 27(6):1432-1438. PubMed ID: 32936721
[TBL] [Abstract][Full Text] [Related]
12. Profile of adverse events in patients receiving treatment for malaria in urban Ghana: a cohort-event monitoring study.
Dodoo AN; Fogg C; Nartey ET; Ferreira GL; Adjei GO; Kudzi W; Sulley AM; Kodua A; Ofori-Adjei D
Drug Saf; 2014 Jun; 37(6):433-48. PubMed ID: 24788801
[TBL] [Abstract][Full Text] [Related]
13. Validation Rules as a First Step for Data Quality: Pharmacovigilance Application in Portugal.
Costa B; Figueiredo B; Pinheiro V
Stud Health Technol Inform; 2023 May; 302():382-383. PubMed ID: 37203696
[TBL] [Abstract][Full Text] [Related]
14. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions in adolescents: a review of reporting to a national pharmacovigilance system.
Rebelo Gomes E; Ribeiro-Vaz I; Santos CC; Herdeiro MT
Expert Opin Drug Saf; 2020 Jul; 19(7):915-922. PubMed ID: 32422079
[TBL] [Abstract][Full Text] [Related]
17. Active Pharmacovigilance Study: A Follow-Up Model of Oral Anti-Cancer Drugs under Additional Monitoring.
Carvalho da Silva SP; Jesus M; Roque F; Herdeiro MT; Costa E Sousa R; Duarte AP; Morgado M
Curr Oncol; 2023 Apr; 30(4):4139-4152. PubMed ID: 37185428
[TBL] [Abstract][Full Text] [Related]
18. Integrating pharmacovigilance into the routine of pharmacy department: experience of nine years.
Pérez-Ricart A; Gea-Rodríguez E; Roca-Montañana A; Gil-Máñez E; Pérez-Feliu A
Farm Hosp; 2019 Jul; 43(4):128-133. PubMed ID: 31276445
[TBL] [Abstract][Full Text] [Related]
19. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
Geer MI; Koul PA; Tanki SA; Shah MY
J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
[TBL] [Abstract][Full Text] [Related]
20. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].
Patrignani A; Palmieri G; Ciampani N; Moretti V; Mariani A; Racca L
G Ital Cardiol (Rome); 2018 Jan; 19(1):54-61. PubMed ID: 29451510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
